The FDA approved belzutifan as the first oral therapy for advanced or metastatic pheochromocytoma and paraganglioma in ...

During a live event, Karen Seiter, MD, discussed the role of the JAK/STAT pathway in myeloproliferative neoplasms and the use ...

Data from the phase 2 ROME trial were presented by Andrea Botticelli, MD, during the ESMO Targeted Anticancer Therapies ...

A panelist discusses how neuroendocrine tumors are defined by World Health Organization (WHO) classification, graded based on ...

Ariel Lopez-Chavez, MD, medical oncologist, director of precision medicine and developmental therapeutics at Allegheny Health Network Cancer Institute, discusses comprehensive genomic profiling and ...

Douglas A. Tremblay, MD, discusses the importance of quality-of-life data from treating patients with polycythemia vera with ...

Panelists discuss how polycythemia vera treatment follows a risk-stratified approach, with all patients receiving daily aspirin and phlebotomies to maintain hematocrit below 45%, while high-risk ...

Panelists discuss how managing advanced polycythemia vera requires tailored approaches beyond hydroxyurea when patients show resistance (persistent hematocrit >45%, elevated white blood cell counts, ...

A panelist discusses how first-line treatment options for neuroendocrine tumors depend on tumor grade, disease extent, and symptoms, ranging from observation for asymptomatic cases to somatostatin ...

Ciara Freeman, MD, PhD, discusses anito-cel's unique functions and benefits for treating multiple myeloma. In an interview with Targeted Oncology TM, Ciara Freeman, MD, medical oncologist at Moffitt ...